AnGes, Inc. (4563.T)
JPY 65.0
(1.56%)
JPY 65.0
(1.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 152.98 Million JPY | 128.13% |
| 2022 | 67.06 Million JPY | 4.54% |
| 2021 | 64.14 Million JPY | 60.38% |
| 2020 | 39.99 Million JPY | -87.76% |
| 2019 | 326.75 Million JPY | -46.44% |
| 2018 | 610.05 Million JPY | 67.05% |
| 2017 | 365.18 Million JPY | -28.99% |
| 2016 | 514.26 Million JPY | 19.55% |
| 2015 | 430.15 Million JPY | -52.73% |
| 2014 | 909.92 Million JPY | 85.2% |
| 2013 | 491.31 Million JPY | 10.53% |
| 2012 | 444.5 Million JPY | 82.63% |
| 2011 | 243.39 Million JPY | -15.17% |
| 2010 | 286.91 Million JPY | -51.01% |
| 2009 | 585.69 Million JPY | -38.42% |
| 2008 | 951.14 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 113.56 Million JPY | 125.65% |
| 2024 Q2 | 234.01 Million JPY | 106.07% |
| 2023 Q1 | 16.6 Million JPY | -21.53% |
| 2023 Q4 | 50.32 Million JPY | -2.15% |
| 2023 Q2 | 34.62 Million JPY | 108.55% |
| 2023 FY | 152.98 Million JPY | 128.13% |
| 2023 Q3 | 51.43 Million JPY | 48.55% |
| 2022 Q2 | 16.49 Million JPY | 7.23% |
| 2022 Q4 | 21.15 Million JPY | 50.91% |
| 2022 Q1 | 15.38 Million JPY | -21.6% |
| 2022 FY | 67.06 Million JPY | 4.54% |
| 2022 Q3 | 14.01 Million JPY | -15.03% |
| 2021 Q2 | 11.54 Million JPY | -0.03% |
| 2021 Q4 | 19.62 Million JPY | -8.44% |
| 2021 FY | 64.14 Million JPY | 60.38% |
| 2021 Q3 | 21.43 Million JPY | 85.74% |
| 2021 Q1 | 11.54 Million JPY | -0.7% |
| 2020 Q4 | 11.62 Million JPY | 0.82% |
| 2020 Q2 | 11.11 Million JPY | 93.89% |
| 2020 Q1 | 5.73 Million JPY | 106.15% |
| 2020 Q3 | 11.53 Million JPY | 3.76% |
| 2020 FY | 39.99 Million JPY | -87.76% |
| 2019 Q1 | 75.55 Million JPY | -77.36% |
| 2019 FY | 326.75 Million JPY | -46.44% |
| 2019 Q3 | 151.39 Million JPY | 56.03% |
| 2019 Q2 | 97.02 Million JPY | 28.41% |
| 2019 Q4 | 2.78 Million JPY | -98.16% |
| 2018 Q2 | 102.23 Million JPY | 38.59% |
| 2018 Q1 | 73.77 Million JPY | -32.84% |
| 2018 Q3 | 100.33 Million JPY | -1.86% |
| 2018 FY | 610.05 Million JPY | 67.05% |
| 2018 Q4 | 333.7 Million JPY | 232.59% |
| 2017 Q2 | 85.93 Million JPY | 3.17% |
| 2017 FY | 365.18 Million JPY | -28.99% |
| 2017 Q4 | 109.84 Million JPY | 27.56% |
| 2017 Q3 | 86.11 Million JPY | 0.21% |
| 2017 Q1 | 83.29 Million JPY | -67.71% |
| 2016 Q4 | 257.95 Million JPY | 198.1% |
| 2016 Q3 | 86.53 Million JPY | -0.06% |
| 2016 Q2 | 86.58 Million JPY | 4.09% |
| 2016 Q1 | 83.18 Million JPY | -24.42% |
| 2016 FY | 514.26 Million JPY | 19.55% |
| 2015 Q2 | 158.32 Million JPY | 93.29% |
| 2015 FY | 430.15 Million JPY | -52.73% |
| 2015 Q1 | 81.9 Million JPY | -86.96% |
| 2015 Q3 | 79.85 Million JPY | -49.56% |
| 2015 Q4 | 110.06 Million JPY | 37.83% |
| 2014 Q1 | 82.71 Million JPY | -17.25% |
| 2014 FY | 909.92 Million JPY | 85.2% |
| 2014 Q2 | 91.78 Million JPY | 10.96% |
| 2014 Q4 | 628.06 Million JPY | 485.02% |
| 2014 Q3 | 107.35 Million JPY | 16.97% |
| 2013 Q4 | 99.96 Million JPY | 30.78% |
| 2013 FY | 491.31 Million JPY | 10.53% |
| 2013 Q3 | 76.43 Million JPY | -59.54% |
| 2013 Q2 | 188.91 Million JPY | 49.95% |
| 2013 Q1 | 125.99 Million JPY | 52.93% |
| 2012 Q2 | 220.09 Million JPY | 221.91% |
| 2012 Q4 | 82.38 Million JPY | 11.85% |
| 2012 Q3 | 73.65 Million JPY | -66.53% |
| 2012 FY | 444.5 Million JPY | 82.63% |
| 2012 Q1 | 68.37 Million JPY | 3.04% |
| 2011 Q4 | 66.35 Million JPY | 24.62% |
| 2011 Q1 | 70.59 Million JPY | -29.07% |
| 2011 Q2 | 53.2 Million JPY | -24.63% |
| 2011 Q3 | 53.24 Million JPY | 0.07% |
| 2011 FY | 243.39 Million JPY | -15.17% |
| 2010 Q1 | 75.08 Million JPY | -21.82% |
| 2010 Q2 | 40.41 Million JPY | -46.17% |
| 2010 Q4 | 99.52 Million JPY | 38.45% |
| 2010 Q3 | 71.88 Million JPY | 77.86% |
| 2010 FY | 286.91 Million JPY | -51.01% |
| 2009 Q3 | 116.05 Million JPY | -40.56% |
| 2009 FY | 585.69 Million JPY | -38.42% |
| 2009 Q2 | 195.23 Million JPY | 9.45% |
| 2009 Q4 | 96.04 Million JPY | -17.24% |
| 2009 Q1 | 178.36 Million JPY | 0.0% |
| 2008 FY | 951.14 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 96.793% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -35.474% |
| GNI Group Ltd. | 26.01 Billion JPY | 99.412% |
| Linical Co., Ltd. | 12.3 Billion JPY | 98.757% |
| Trans Genic Inc. | 13.08 Billion JPY | 98.831% |
| MEDINET Co., Ltd. | 661.54 Million JPY | 76.875% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 97.034% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 90.196% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | 74.925% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 98.802% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 81.268% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -12.897% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | 90.591% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 64.286% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 91.953% |
| Chiome Bioscience Inc. | 682.46 Million JPY | 77.583% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 93.708% |
| PeptiDream Inc. | 28.71 Billion JPY | 99.467% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -142.687% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -26.434% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -212379.167% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -283.546% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 96.608% |
| FunPep Company Limited | 530 Thousand JPY | -28765.094% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -120.917% |
| Stella Pharma Corporation | 269.49 Million JPY | 43.232% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | 51.712% |
| Cuorips Inc. | 23.1 Million JPY | -562.215% |
| K Pharma,Inc. | 1 Billion JPY | 84.702% |
| Takara Bio Inc. | 43.5 Billion JPY | 99.648% |
| ReproCELL Incorporated | 2.42 Billion JPY | 93.696% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 91.081% |
| StemCell Institute Inc. | 2.48 Billion JPY | 93.834% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 93.915% |
| CellSeed Inc. | 190.13 Million JPY | 19.538% |